OncLive® On Air
by OncLive® On Air
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇸🇦SA · Health & Fitness#953K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
900 to 3K🎙 Daily cadence·500 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
3K to 10K🇸🇦100% - Active Followers
Loyal subscribers who consistently listen
900 to 3K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 34 epsHosts
Recent guests
Recent episodes
S17 Ep59: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions
Jul 21, 2026
20m 03s
S17 Ep58: DLBCL 2026 UPDATE
Jul 20, 2026
12m 50s
S17 Ep57: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC
Jul 20, 2026
37m 44s
S17 Ep56: Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS
Jul 17, 2026
15m 16s
S17 Ep55: Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis
Jul 17, 2026
28m 36s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/21/26 | antibody-drug conjugatesbispecific antibodies+5 | William J. Gradishar, MD, FASCO, FACPRebecca Arend, MD, MSPH+2 | PER® (Physicians’ Education Resource®, LLC) | — | CMEcancer treatment+3 | BioNTech | 20m 03s | ||
| 7/20/26 | diffuse large B-cell lymphomaoncology+4 | — | Indiana University HealthUniversity of Illinois | — | DLBCLoncology+5 | — | 12m 50s | ||
| 7/20/26 | immunotherapynon-small cell lung cancer+4 | Tina Cascone, MD, PhDPuneeth Iyengar, MD, PhD+1 | PER® (Physicians’ Education Resource®, LLC) | — | CMENSCLC+4 | AstraZeneca Pharmaceuticals | 37m 44s | ||
| 7/17/26 | systemic therapycutaneous squamous cell carcinoma+4 | Neil D. Gross, MD, FACS | cemiplimab-rwlc (Libtayo)The University of Texas MD Anderson Cancer Center | — | CSCCBCC+5 | — | 15m 16s | ||
| 7/17/26 | myelofibrosispatient care+3 | Ruben Mesa, MD, FACPAndrew Kuykendall, MD+1 | PER® (Physicians’ Education Resource®, LLC) | — | myelofibrosisCME+3 | Bristol Myers Squibb | 28m 36s | ||
| 7/16/26 | non-small cell lung cancertargeted therapy+3 | Justin Gainor, MDJulia Rotow, MD+1 | PER® (Physicians’ Education Resource®, LLC)BioNTech+5 | — | NSCLCtargeted therapies+4 | — | 31m 16s | ||
| 7/15/26 | OncologyBreast Cancer+4 | Virginia Kaklamani, MD, DScKamel Abou Hussein, MD+2 | American Society of Clinical OncologyPER® (Physicians’ Education Resource®, LLC) | — | oral SERDsHR-positive breast cancer+4 | Stemline Therapeutics, Inc. | 30m 32s | ||
| 7/14/26 | oral SERD-based therapyCDK4/6 inhibition+3 | Virginia Kaklamani, MD, DScAntonio Giordano, MD, PhD+6 | PER® (Physicians’ Education Resource®, LLC) | — | oral SERDCDK4/6+3 | Stemline Therapeutics, Inc. | 30m 26s | ||
| 7/13/26 | chemotherapy-induced thrombocytopeniaoncology+4 | Gerald Soff, MD | romiplostimUniversity of Miami Miller School of Medicine+1 | — | chemotherapythrombocytopenia+5 | — | 13m 12s | ||
| 7/13/26 | hepatobiliary cancerimmunotherapies+3 | Ghassan Abou-Alfa, MD, JD, MBA, PhD (hc)Riad Salem, MD, MBA+2 | PER® (Physicians’ Education Resource®, LLC) | — | CMEhepatobiliary cancer+5 | AstraZeneca Pharmaceuticals | 29m 05s | ||
| 6/10/26 | multiple myelomaEHA Congress+3 | Joshua Richter, MD | Tisch Cancer InstituteBlavatnik Family-Chelsea Medical Center | New York, New YorkStockholm, Sweden | multiple myelomaEHA 2026+3 | — | 10m 21s | ||
| 6/8/26 | oncologypancreatic cancer+3 | — | daraxonrasib (RMC-6236)Indiana University Health+1 | — | RASolute 302daraxonrasib+3 | — | 11m 27s | ||
| 6/5/26 | molecular profilingglioma+4 | Manmeet Ahluwalia, MD, MBAAshley S. Margol, MD, MS | OncLive® On Air | — | gliomatargeted therapy+4 | — | 31m 56s | ||
| 6/1/26 | radiation therapysystemic therapy+4 | Binh T. Ngo, MD | Keck School of Medicine of the University of Southern CaliforniaUSC Norris Comprehensive Cancer Center+1 | — | radiation oncologyskin cancer treatment+4 | — | 29m 32s | ||
| 5/28/26 | molecular testingnon-small cell lung cancer+3 | Anthony Chi, MDMonica Peravali, MD+1 | Mid-Atlantic Permanente Medical GroupKaiser Permanente+1 | Maryland | molecular testingNGS+5 | — | 30m 12s | ||
| 5/27/26 | cervical cancerimmunotherapy+4 | Meghan E. Shea, MD | pembrolizumabDana-Farber Cancer Institute+2 | Boston, Massachusetts | cervical cancerHPV vaccination+5 | — | 15m 34s | ||
| 5/26/26 | small cell lung cancerimmunotherapy+3 | Jacob Sands, MDJacob Sands | tarlatamab-dlle (Imdelltra)rovalpituzumab tesirine (Rova-T)+2 | — | small cell lung cancerimmunotherapy+4 | — | 24m 59s | ||
| 5/23/26 | TKIschronic myeloid leukemia+3 | Michael J. Mauro, MDMichael J. Mauro | dasatinibMemorial Sloan Kettering Cancer Center | New York | TKIsCML+5 | — | 16m 59s | ||
| 5/20/26 | ESR1 mutation testingmetastatic breast cancer management+4 | Pedram Razavi, MD, PhDDara S. Ross, MD | camizestrantaromatase inhibitors+2 | — | ESR1 mutationsbreast cancer+6 | — | 37m 01s | ||
| 5/13/26 | esophageal cancerdiagnosis+3 | Peter Enzinger, MDPeter Enzinger | zanidatamab-hrii (Ziihera)pembrolizumab (Keytruda)+3 | — | esophageal cancerdiagnosis+5 | — | 9m 36s | ||
| 5/13/26 | FDA approvalbrexucabtagene autoleucel+4 | Luhua (Michael) Wang, MD | brexucabtagene autoleucelTecartus+1 | Houston | brexucabtagene autoleucelFDA approval+7 | — | 20m 46s | ||
| 5/12/26 | breast cancersurvivorship+3 | Annie Bond | Tennessee Oncology | — | breast cancersurvivorship+5 | — | 48m 41s | ||
| 5/8/26 | biomarker-directed therapiesgastrointestinal oncology+3 | Michael J. Pishvaian, MD, PhDMichael J. Pishvaian | zanidatamabJohns Hopkins Kimmel Cancer Center+1 | — | biomarkersGI oncology+3 | — | 22m 55s | ||
| 5/6/26 | non-small cell lung cancerprecision care+3 | Sanja Dacic, MD, PhDIsabel Preeshagul, DO, MBS+1 | OncLive® On Air | — | non-small cell lung cancerpathology+3 | — | 30m 49s | ||
| 5/4/26 | metastatic bladder cancerurothelial carcinoma+4 | — | enfortumab vedotinpembrolizumab+2 | — | metastatic bladder cancerurothelial carcinoma+6 | — | 9m 20s |
Showing 25 of 25
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Two Onc Docs
Sam and Karine
Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
Oncology Today with Dr Neil Love
Dr. Neil Love
Research To Practice | Oncology Videos
Dr Neil Love
ASCO Daily News
American Society of Clinical Oncology (ASCO)
The Headlines
The New York Times
Lung Cancer Considered
IASLC
Chart history for OncLive® On Air
Peaked at #95 in SA, currently #95 in SA.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| SA | — | #95 | #95 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.